Abstract 401TiP
Background
As reported in our previous study (Lin, JNCCN 2021) intravenous (i.v.) opioid titration with PCA provides earlier analgesia and higher patient satisfaction for pain control compared with conventional titration administrated by medical staff. After successful opioid titration, it is appropriate to maintain analgesia with regularly scheduled medication plus supplemental doses for breakthrough cancer pain (BTcP). Compared with regularly scheduled doses, continuous infusion using a PCA pump can confer a more stable and effective plasma concentration to control background pain. An on-demand bolus dose allows patients to voluntarily control BTcP. Therefore, continuous infusion plus an on-demand bolus dose may maximize the benefits of i.v. PCA (IPCA) for maintenance therapy. Our previous phase II study (Lin, JNCCN 2022) reported that IPCA was superior to oral administration as maintenance analgesia for severe cancer pain. IPCA with continuous infusion vs. without continuous infusion (bolus-only) may not be different in terms of pain control. IPCA without continuous infusion may consume less opioid. Therefore, in this study we aim to confirm these findings in a phase III study with a larger sample size.
Trial design
This is a multicenter open-label randomized controlled phase III trial. Eligibility criteria include: patients who are diagnosed with a malignant solid tumor by pathology or cytology and who have had persistent severe cancer-related pain (≥7 at rest on the 11-point Numeric Pain Rating Scale [NRS]); age 18 to 80 years; and ECOG PS≤3. Patients were randomly assigned in a 2:2:1 ratio to 1 of 3 arms: (A1) IPCA hydromorphone with bolus-only dose as needed (PRN); (A2) IPCA hydromorphone with continuous infusion for background pain plus bolus for BTcP; or (B) oral extended-release morphine around the clock for background pain and normal-release morphine PRN for BTcP. The primary endpoint was average NRS over days 1-3 (sum of previous 24-hour average pain scores for days 1–3 divided by 3). Enrollment is ongoing.
Clinical trial identification
NCT04785768.
Legal entity responsible for the study
The authors.
Funding
Guiding Project of Fujian Province (No.2023Y0057).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract